Sector Experience

Healthcare
Life Sciences & Pharma

Experience

Taylor Global Biopharma Consulting Management Consulting
Principal
5/2020 - Present
- Providing strategic consulting services to biopharmaceutical companies based on twenty years of
deep Commercial and Drug Development experience across multiple blockbuster Oncology brands.
- Clients include Olema Oncology and several clinical stage biotechnology firms.
- Senior Advisor to McKinsey and Company.
Genetics Management Consulting
Chief Commercial Officer, Executive Vice-President,
5/2019 - 2/2020
- Led a 300-person Commercial organization, including global and US marketing and sales, market access and market analytics.
- Grew Adcetris (anti-CD30 antibody drug-conjugate) sales to $628M in US & Canada in 2019 (32% increase over 2018).
- Successfully launched Padcev (anti-Nectin4 antibody drug-conjugate) for metastatic bladder cancer,
co-commercialized with Astellas.
AstraZeneca Management Consulting
Vice-President, Immuno-Oncology Franchise Head, Oncology Business Unit
11/2018 - 4/2019
Led the Immuno-Oncology (IO) Franchise of four IO Global Medicine Leaders (who lead the Global
Product Teams), and a Global Marketing Team of 20 marketers.
- Led the IO Franchise team – a cross-functional group accountable for the overall development and commercialization strategy for IMFINZI and tremelimumab, and the long-term strategy for
- Immuno-Oncology at AstraZeneca.
Roche Group Management Consulting
Vice-President, Cancer Immunotherapy Franchise Head, Global Product Strategy
1/2015 - 1/2018
-Led a Franchise of four Tecentriq (atezolizumab, anti-PD-L1) lifecycle teams, and 18 team members (eight directs) responsible for the global development, launch and commercialization of Tecentriq.
-Created new lifecycle teams for CEA T-Cell Bispecific and iNEST (Individualized NeoAntigen Specific Immunotherapy) upon transition from early clinical development.
-Co-Leader of the Cancer Immunotherapy Committee (CITC) – a cross-functional team of the Group
-Heads of Oncology
Roche Group Management Consulting
Vice-President, Lung & Cancer Immunotherapy, Global Product Strategy
1/2014 - 1/2015
-Led a Franchise of 16 team members responsible for the global development and commercialization of Tecentriq (atezolizumab, anti-PD-L1), Alecensa (alectinib, ALK inhibitor), and Tarceva (erlotinib, EGFR inhibitor).
-Created and Co-chaired the Cancer Immunotherapy Committee – a cross-functional team across gRED, pRED and late stage organization actively engaged in advancing the development of cancer immunotherapy drugs and biomarkers within and beyond the Roche/Genentech cancer immunotherapy
Genentech Corporate Strategy & Development
Lifecycle Leader, MetMAb, Global Product Strategy
1/2010 - 1/2014
-Led the global development, manufacturing, and commercialization of onartuzumab (MetMAb), a monovalent monoclonal antibody targeting the MET receptor with a novel companion diagnostic MET IHC assay co-developed with Ventana Medical Systems (Roche Diagnostics).
Genentech Management Consulting
Head, Oncology Pipeline, Global Product Strategy
1/2009 - 1/2010
-Created and led a new Oncology Pipeline group of five Disease Area Directors to provide business guidance on indication selection, target product profiles, and overall molecule strategy for over 35 early development programs in Genentech and Pharma Research and Early Development (gRED and pRED).
-Developed a new business process for all therapeutic areas within GPS, including the formation of an Early Business Review Committee to approve Target Product Profiles (TPPs) and product forecasts.